Variants of the novel coronavirus which carry two specific mutations in their spike protein may elude the antibodies, making vaccine against COVID-19 less effective, said virologist, Shahid Jameel adding that improving surveillance on for "homegrown" lineages of the coronavirus is the need of the hour.

Jameel, who serves as the Director of the Trivedi School of Biosciences at Ashoka University in Haryana further stated that these mutations would bring about a dramatic change in protein structure that creates a bind with antibodies. This process will abate vaccine’s efficiency.

Also Read: Pune imposes night curfew in wake of rising coronavirus cases


The spike protein of the novel coronavirus makes it possible for it to bind to the ACE2 receptor on host cells. According to several studies, this process is believed to be imperial for this virus to enter a body and cause infection.

According to the noted virologist, currently, the data is consistent with poor activity of neutralising antibodies against the South African lineage of the coronavirus, which carries both these mutations on the spike protein.

At GYANTEEKA, an online presentation-discussion series hosted by the Indian National Young Academy of Science (INYAS), New Delhi to spread awareness and bust myths on vaccines, Jameel said these mutations are in the 501st and 484th amino acid building blocks that make up the virus spike protein.


In his presentation on Saturday, the noted virologist said both these mutations happen at the interface where antibodies bind to the virus spike protein.

Also Read: India records 14,264 new COVID-19 cases, 90 deaths in past 24 hours

"At the interface, there are a couple of key amino acid residues. One is the N501Y mutation. Another emerging mutation is the E484K mutation, and if you notice, the 484 changes negatively charged amino acid into positively charged amino acid," he explained in his presentation, citing studies.


"If you have both 501 and 484 mutations happening at the same time in the same virus, that virus is likely to either evade antibody response, or it is going to make the antibodies less effective. That's the take-home," he added.

On Tuesday, the Health ministry said four people in the country tested positive for infection with the South African variant, and one for the Brazil variant -- a first for India.

While in India, there have not been reports of community transmission of these virus, Jameel believes the need of the hour is also to look out for homegrown variants. "Remember India already has about 11 million infections now, so there could easily be homegrown variants and I think for that it is very important to have genomic surveillance, which is done at scale," the virologist said.


"And for that government of India has set up an inter-ministerial Group which is called INSA COG which brings together 10 different National Laboratories to start sequencing at a density of about 5 per cent," he added.

Currently, the virologist said India is sequencing at a density of about 0.05 per cent.

"So essentially, the plan is to upscale sequencing about a hundredfold in the country," Jameel added.


A recent study by the scientists of CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad analysed over 5,000 coronavirus variants, describing how the virus has evolved over the course of the pandemic.

Also Read: Peru undergoes scarcity of medical oxygen after rise in COVID-19 cases

It found that a variant carrying the N440K mutation is spreading a lot more in the southern states of India.


"We now have emerging evidence that the N440K variant is spreading a lot more in southern states. Closer surveillance is needed to understand its spread properly," CCMB Director Rakesh Mishra said in a statement.

While variants with immune-escape such as the South African variant have been identified with only a low prevalence in India, Mishra believes this could be because not enough sequencing has been done.

"More coronavirus genomes need to be sequenced across the country to accurately identify the emergence of these and other new variants," he added.